Benlysta, a drug to treat lupus, has received approval from European regulators to be marketed in Europe, the drug’s co-makers, Human Genome Sciences Inc. of Rockville, and GlaxoSmithKline, its London-based parent, announced.
The European approval came two days after Benlysta, the first new treatment developed for lupus in 50 years, was approved for use in Canada.